An update from Sernova ( (TSE:SVA) ) is now available.
Sernova Biotherapeutics has submitted an Investigational New Drug application to the FDA for its Cell Pouch bio-hybrid organ combined with autograft thyroid cells, targeting patients with hypothyroidism following thyroidectomy. This innovative approach aims to provide a long-term solution for restoring natural thyroid function without immune suppression therapy, potentially transforming treatment for endocrine disorders. Preclinical trials have shown promising results, and pending FDA clearance, Sernova plans to initiate human trials to assess safety and efficacy.
More about Sernova
Sernova Biotherapeutics is a clinical-stage company specializing in regenerative medicine therapeutics. The company focuses on developing bio-hybrid organs by combining its Cell Pouch technology with human donor cells or stem cell-derived cell therapies, aiming to treat chronic diseases such as type 1 diabetes and thyroid disorders.
YTD Price Performance: -4.35%
Average Trading Volume: 120,074
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$72.27M
For detailed information about SVA stock, go to TipRanks’ Stock Analysis page.